Corpus ID: 2129509

Malignant Melanomas CpG Islands in Putative Promoter Regions in Human and Aberrant Methylation of 33 Peroxiredoxin 2 Silencing of Updated

  title={Malignant Melanomas CpG Islands in Putative Promoter Regions in Human and Aberrant Methylation of 33 Peroxiredoxin 2 Silencing of Updated},
  author={J. Furuta and Y. Nobeyama and Y. Umebayashi and F. Otsuka and Kanako Kikuchi and T. Ushijima},
Aberrant methylation of promoter CpG islands (CGI) is involved in silencing of tumor suppressor genes and is also a potential cancer biomarker. Here, to identify CGIs aberrantly methylated in human melanomas, we did a genomewide search using methylation-sensitive representational difference analysis. CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12… Expand

Figures and Tables from this paper


Identification of 20 genes aberrantly methylated in human breast cancers
It was showed that breast cancer cells accumulate aberrant methylation of the CGI, which may serve as markers for early‐stage breast cancers and suggests that aberrantmethylation targets transcriptionally inactive genes in vivo. Expand
Promoter methylation profiling of 30 genes in human malignant melanoma
These profiles showed that both aberrant methylation and demethylation occur widely in human melanomas. Expand
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
The findings indicate that the incidence of TSG hypermethylation increases during tumor progression and may play a significant role in cutaneous melanoma progression. Expand
Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers
Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA), and some were suggested to be potentially involved in pancreatic cancer development and progression. Expand
Aberrant methylations in cancer cells: Where do they come from?
An assay system to detect demethylating agents, and an assay system for methylating agents is necessary are developed, which strongly supports the presence of CIMP, but it seems to contain multiple entities. Expand
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
  • R. van Doorn, W. Zoutman, +9 authors C. Tensen
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Malignant T cells of patients with CTCL display widespread promoter hypermethylation associated with inactivation of several tumor suppressor genes involved in DNA repair, cell cycle, and apoptosis signaling pathways, and may be amenable to treatment with demethylating agents. Expand
Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells
The results support a model that requires a combination of prior gene silencing and random ‘seeds’ of methylation to trigger hypermethylation of the GSTP1 gene in the prostate cancer cell. Expand
Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor Cells
It is concluded that the site-specific hypomethylation of MAGE-A1 in tumor cells relies on a transient process of demethylation followed by a persistent local inhibition of remethylation due to the presence of transcription factors. Expand
Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors.
Comparison MS-RDA of one hepatocellular carcinoma and of background liver tissue of one mouse treated with a food carcinogen and a methylation-sensitive-representational difference analysis method, which is a promising approach to identify DNA fragments differentially methylated in two DNA sources. Expand
Genetic and epigenetic alterations of the APC gene in malignant melanoma
It is proposed that epigenetic silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the expression of APC to a level that promotes cell proliferation without compromising the invasive capacity. Expand